IMPALA ERASNCT07224711
The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Oct 31, 2026 to Oct 26, 2026
- Site details revised
- Notable Eligibility criteria expanded, about 14 words
- Interventions modified
- Secondary endpoints: details revised at 3 of 7 entries
- Notable Start date: Jul 1, 2026 to Oct 31, 2026
- Primary and study completion pushed from May 30, 2028 to Oct 31, 2028
- Notable Start date: Jun 1, 2026 to Jul 1, 2026
- Eligibility criteria shortened, about 12 words
- Primary endpoints: 1 to 2
- Study title revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Participants randomized to receive 1.5 mg /kg bolus of 0.8% lidocaine Hydrochoride (HCL) in dextrose 5% in water (D5W) via IV with induction, prior to infusion started. The IV bolus will be followed by continuous IV infusion of 2 mg/minute of 0.8% lidocaine HCl in D5W intraoperatively with weight-based gradated dosing postoperatively (1-2 mg/minute)
Participants randomized to receive dextrose 5% in water (D5W) via IV with induction, prior to infusion started. The IV bolus will be equivalent in volume to the lidocaine arm. The bolus will be followed by continuous IV infusion intraoperatively and then up to 48 hours. The continuous IV infusion will be equivalent in volume and rate to the lidocaine arm.
Drugs: Lidocaine HCl 0.8% in D5W, Dextrose 5% in water
Sites
1 site in 1 country
- Vanderbilt University Medical CenterNashville, Tennessee, United States